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a b s t r a c t
5q minus syndrome is a form of myelodysplastic syndrome characterized by the pre-
sence of an isolated deletion of long arm of the chromosome 5. Patients with 5q minus
respond well to the treatment with lenalidomide. The presence of the JAK2 V617F muta-
tion is a common feature of refractory anemia with ring sideroblasts and marked throm-
bocytosis. Much less is known about effectiveness of lenalidomide in these patients. We
present the patient with 5q minus syndrome and JAK2 V617F mutation accompanied by
the presence of ringed erythroblasts meeting the criteria of RARS-T. We could identify
only two such patients reported in the literature; no details were given about effective-
ness of lenalidomide in that group. We observed good response to the treatment with
lenalidomide with transfusion independence 9 months after starting of the treatment;
however, there was no complete eradication of del (5)(q13q31) clone nor the clone with
JAK V617F mutation.
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disease has a relatively good prognosis, the overall survival
rate is estimated at approximately 145 months and the risk
of transformation to acute myeloid leukemia is less than
10% [2, 3]. In a small percentage of cases, patients withb Rozrostowych Układu Krwiotwórczego Szpital Uniwersytecki
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Fig. 1 – Five erythroblasts (arrows), at different stage of
maturation, show dysplastic features (megaloid changes,
cytoplasmic vacuoles, irregular shape of nucleus, abnormal
hemoglobinisation)
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authors of the fourth edition of WHO Classification of
Tumors of Hematopoietic and Lymphoid Tissues (WHO
2008) separated JAK2 V617F mutated form that emerged
from the typical 5q minus syndrome. In their opinion, there
is not enough data collected for accurate classification of
this subgroup. It was decided that temporarily the diagnosis
should be classified as MDS, not as a myeloproliferative
disease, with the addition of information about the presence
of the JAK2 V617F mutation [5, 6]. On the other hand, the
presence of the JAK2 V617F mutation is a common feature
of refractory anemia with ring sideroblasts and marked
thrombocytosis (RARS-T), which was included into “Myelo-
dysplastic/myeloproliferative neoplasm, unclassifiable” as
a provisional entity grouping together patients with the
diseases having features of myelodysplastic and myeloproli-
ferative disease [7, 8]. Patients with 5q minus syndrome
usually respond well to the treatment with lenalidomide [9–
11]. Much less is known about its effectiveness in the
patients meeting the criteria of RARS-T [12, 13]. In this
paper, we present the case of a patient with 5q minus
syndrome with JAK2 V617F mutation features and ringed
erythroblasts accompanied by thrombocytosis effectively
treated with lenalidomide.
A case report
A 59-year-old female patient was admitted to the depart-
ment of hematology due to persistent macrocytic anemia
with hemoglobin 9.9 g/dl (mean cell volume – MCV –
104.3 fl), white cell count 9.50 G/l, and with platelet countFig. 2 – Two ringed sid944  109/l. Before she was referred to a hematologist, she
had been unsuccessfully treated with vitamin B12. At the
time of her first presentation, the bone marrow showed 60%
cellularity with numerous dysplastic megakaryocytes pre-
senting large hypolobated nuclei and with features of
erythroid dysplasia (Fig. 1). Ringed sideroblasts accounted
for 18% of her erythroid precursors (Fig. 2). Blast cells
expressing CD34 antigen accounted for approximately 3% oferoblasts (arrows)
Fig. 3 – Two large hypolobated and one smaller, bi-nuclear,
immature megakaryocytes
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present, including some with hypolobated nuclei (Fig. 3).
The cytogenetic analysis revealed a deletion of the long arm
of chromosome 5: 46, XX, del (5)(q13q31) [13]/46, XX. PCR
studies did not show the presence of the JAK2 V617F
mutation at that time.
Once the diagnosis was established, the patient remained
under observation, with a sporadic, intermittent require-
ment of a blood transfusion, and required occasional blood
transfusions. After 21 months of follow-up outpatient mon-
itoring, significant worsening of the anemia was noticed
and it was decided to commence the treatment with
lenalidomide. At that time, the biopsy showed 70% marrow
cellularity with large, dysplastic megakaryocytes, and dyser-
ythropoiesis. No increase in blast percent was found. At this
point, the PCR test revealed the presence of JAK2 V617F
mutation for the first time.
Lenalidomide therapy was introduced, initially at a dose
of 10 mg per day, later reduced to 5 mg per day due to
neutropenia. After 12 weeks of that treatment an indepen-
dence from blood transfusions was achieved. The current
level of hemoglobin, evaluated 9 months after the treatment
was first introduced, is 11.8 g/dl at MCV of 95.7 fl and the
platelet count of 126  109/L. The lenalidomide treatment is
continued at the dose of 5 mg per day. Despite clinical
improvements, the 5q () clone is still present and the
molecular analysis shows the presence of JAK2 V617F
mutation. Dysplastic features also continue to persist in the
marrow.
Discussion
The accurate classification of 5q minus syndrome with
a JAK2 V617F mutation is yet not determined, especially in
patients with additional presence of ring sideroblasts. The
case described above responded well to the treatment with
lenalidomide, which is commonly seen in patients withisolated 5q minus deletion MDS but much less often in
patients with other types of low grade MDS [9, 13]. It is on
the other hand very difficult to compare the response to
lenalidomide treatment observed in our patient to similar
cases described in literature. In one of the largest studies,
190 patients with 5q minus syndrome were described by
researchers from the Mayo Hospital. It represented 1% of
over 24 000 unique patient cytogenetic studies performed at
that institution between 1989 and 2009. Among them, 78
patients with the 5q minus syndrome were identified. JAK2
V617F mutation was shown in 5 (6.4%) of them and did not
seem to affect the phenotype or prognosis. Only one of the
presented cases had additional feature of RARS, similar to
that which is observed in our patient [14]. In another study,
Szpurka et al. described 146 patients with RARS, 13 carried
JAK2 V617F mutations and only one of them fulfilled criteria
of 5q minus syndrome [8]. No separate information concern-
ing the outcome of the patient's treatment was given. Huls
et al. described two patients with RARS-t with JAK2 V617F
mutation, who responded to the treatment with lenalido-
mide, with one of them achieving complete molecular
remission [15].
The effectiveness of lenalidomide has also been con-
firmed in the presented case. Despite the reduction of the
initial dose of 10 mg/d to 5 mg per day due to neutropenia,
the patient became completely independent of blood trans-
fusions. However, there was no complete eradication of del
(5)(q13q31) clone nor the clone with JAK V617F mutation. In
a study reported by Fenaux et al. among patients with
classic 5q minus syndrome, cytogenetic remission was
observed in 50% of them treated with 10 mg lenalidomide
daily. Yet, only 25% of patients that received a dose of 5 mg
per day went into cytogenetic remission [11]. At the present
stage, we are not able to find any difference in response to
the treatment with lenalidomide between our patient and
other cases with isolated 5q minus deleted MDS.
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